Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

Filippo De Marinis, V. Gebbia, L. De Petris

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role of induction radiotherapy, as well as definite chemo-radiotherapy in stage IIIA NSCLC. This report review these issues and focuses on current treatment options for resectable stage IIIA-N2 NSCLC.

Original languageEnglish
JournalAnnals of Oncology
Volume16
Issue numberSUPPL. 4
DOIs
Publication statusPublished - May 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Induction Chemotherapy
Platinum
Drug Therapy
Radiotherapy
Therapeutics
Research

Keywords

  • Early stage
  • Molecular markers analysis
  • Neoadjuvant chemotherapy
  • Neoadjuvant radiotherapy
  • NSCLC
  • Stage IIIA-N2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer. / De Marinis, Filippo; Gebbia, V.; De Petris, L.

In: Annals of Oncology, Vol. 16, No. SUPPL. 4, 05.2005.

Research output: Contribution to journalArticle

@article{6768f6e33100428fad232bf0cf9c5a27,
title = "Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer",
abstract = "Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role of induction radiotherapy, as well as definite chemo-radiotherapy in stage IIIA NSCLC. This report review these issues and focuses on current treatment options for resectable stage IIIA-N2 NSCLC.",
keywords = "Early stage, Molecular markers analysis, Neoadjuvant chemotherapy, Neoadjuvant radiotherapy, NSCLC, Stage IIIA-N2",
author = "{De Marinis}, Filippo and V. Gebbia and {De Petris}, L.",
year = "2005",
month = "5",
doi = "10.1093/annonc/mdi920",
language = "English",
volume = "16",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

AU - De Marinis, Filippo

AU - Gebbia, V.

AU - De Petris, L.

PY - 2005/5

Y1 - 2005/5

N2 - Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role of induction radiotherapy, as well as definite chemo-radiotherapy in stage IIIA NSCLC. This report review these issues and focuses on current treatment options for resectable stage IIIA-N2 NSCLC.

AB - Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role of induction radiotherapy, as well as definite chemo-radiotherapy in stage IIIA NSCLC. This report review these issues and focuses on current treatment options for resectable stage IIIA-N2 NSCLC.

KW - Early stage

KW - Molecular markers analysis

KW - Neoadjuvant chemotherapy

KW - Neoadjuvant radiotherapy

KW - NSCLC

KW - Stage IIIA-N2

UR - http://www.scopus.com/inward/record.url?scp=30644468490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644468490&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi920

DO - 10.1093/annonc/mdi920

M3 - Article

C2 - 15923411

AN - SCOPUS:30644468490

VL - 16

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 4

ER -